Toxicity study in rats of a tellurium based immunomodulating drug, AS-101: A potential drug for AIDS and cancer patients

Avraham Nyska, Trevor Waner, Michael Pirak, Michael Albeck, Benjamin Sredni

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Male and female Sprague Dawley rats were injected intraperitoneally for 4 weeks with ammonium trichloro (dioxyethylene-0-0′-) tellurate, an immunomodulating drug at closes ranging from 3 to 24 mg/kg/week. Routine laboratory examinations included body weight, food consumption, clinical chemistry and hematological examinations. At termination of the experiment, all rats were sacrificed and subjected to a detailed necropsy. Few mortalities were recorded during the course of the study. Clinical signs included hind limb paresis and paraphimosis. A garlic odor pervaded the room. Body weight and food consumption were adversely affected in a dose-related manner. Effects were elicited on the hematological system; changes being noted in the platelet and leukocyte counts as well. Clinical chemistry evaluation revealed signs of hepatoxicity, especially in the female treated groups. The level of beta-globulin was increased. At necropsy organs were found to have a grayish-blue discoloration. Tellurium related histopathological changes were observed in the eyes, liver, thymus, bone marrow, heart and kidneys. An attempt has been made to compare the toxicity of this drug with other tellurium-containing compounds. A good correlation was found. Novel effects of the drug were retinopathy and replacement of bone marrow by bony or fibrous tissue. The possibility that some of the effects may have been elicited due to selenium-vitamin E deficiency has been considered.

Original languageEnglish
Pages (from-to)386-393
Number of pages8
JournalArchives of Toxicology
Volume63
Issue number5
DOIs
StatePublished - Sep 1989

Keywords

  • Drug
  • Immunomodulator
  • Rat
  • Tellurium
  • Toxicology

Fingerprint

Dive into the research topics of 'Toxicity study in rats of a tellurium based immunomodulating drug, AS-101: A potential drug for AIDS and cancer patients'. Together they form a unique fingerprint.

Cite this